Orexo Sweden

A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were compared with an oral and an injectable formulation.AmorphOX formulations demonstrated significantly higher plasma concentrations and higher bioavailability than the oral tablet.The data further demonstrate the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules that are well absorbed through mucosal membranes.View original content:https://www.prnewswire.co.uk/news-releases/orexos-amorphox-technology-may-pave-the-way-for-intranasal-glp-1-medication-302547668.html